Block Listing Six Monthly Return

November 15, 2022

15 November 2022

LungLife AI, Inc.

("LungLife" or the "Company")


Block Listing Six Monthly Return 


LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, makes the following six-monthly update on its block listing:


Name of applicant: LungLife AI, Inc.
Name of scheme:
  1. 2010 Stock Incentive Plan
  2. 2020 Stock Incentive Plan
  3. 2021 Omnibus Long-Term Incentive Plan
Number and class of securities originally admitted: 1,356,139 common shares of US $0.0001 each
Date of admission: 15 November 2021
Period of return: From: 15 May 2022 To: 15 November 2022
Balance of unallotted securities under scheme(s) from previous return:
  1. 480,775
  2. 201,374
  3. 673,990
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
  1. NIL
  2. NIL
  3. NIL
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
  1. 5,192
  2. NIL
  3. NIL
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
  1. 475,583
  2. 201,374
  3. 673,990


Name of contact: David Anderson, Chief Financial Officer
Telephone number of contact: +44 (0)20 7933 8780 or

For the full announcement, click HERE.

Recent News

Clinical validation study update
Director share purchases
Half-year Report

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.